

HAMBURG OCTOBER 19-23, 2024 eanm24.eanm.org



Plenary Session 3

Monday, October 21, 2024, 11:30 - 13:00

Session Title

Nuclear Medicine as Answer to all Clinical Questions

Chairpersons

Petra Petranović Ovčariček (Zagreb, Croatia) Margret Schottelius (Lausanne, Switzerland)

Programme

11:30 - 11:45	Jochen Walz (Marseille, France): How PSMA PET has changed our daily work
11:45 - 12:00	Marianne Pavel (Erlangen, Germany): Nuclear Medicine to choose the right treatment for the right patient
12:00 - 12:15	Evelien Smits (Antwerp, Belgium): What has immunoPET to offer
12:15 - 12:30	Maria Mazalena Pizzi (Barcelona, Spain): How molecular imaging has changed patients' management in cardiology
12:30 - 12:45	Rupert Lanzenberger (Vienna, Austria): PET is a clinical need in psychiatry
12:45 - 13:00	Valentin Schäfer (Bonn, Germany): The era of image-driven clinical management in

Educational Objectives

- 1. The impact of PSMA imaging on management of prostate cancer patients
- 2. The role of nuclear medicine imaging on personalized therapy
- 3. Diagnostic and therapeutic options of immunoPET

rheumatological disorders is coming

- 4. Molecular imaging in cardiology improved patient management
- 5. The role of nuclear medicine imaging in psychiatry
- 6. Clinical impact of nuclear medicine in rheumatological diseases

Summary

This session will demonstrate the impact of nuclear medicine imaging on patient management in various areas of medicine. It will emphasize its role in oncology, cardiology, psychiatry, immunology, and rheumatology.

Molecular imaging plays an increasing role in medicine, improving diagnostics in general and enabling the best individualized treatment option for each patient.

Key Words

Molecular imaging; prostate cancer; PSMA; immunoPET; cardiology; rheumatology; psychiatry; theranostics